Answers are grounded in this paper and cite their sources.
Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.
No takes yet. Share an insight, caveat, or question.
Haeberlein et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: